Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAVELIN Ovarian PARP 100
NCT03642132Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Jul 2018
- Primary completion
- Dec 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 10
01
Overview
A Phase 3 trial of avelumab in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Pfizer. Started Jul 2018; status: terminated.
02
Drugs
avelumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT03642132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03642132.